The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/IIa trial of CEND‐1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX).
 
Anup Kasi
Honoraria - OncLive
Research Funding - Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Halozyme (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
Travel, Accommodations, Expenses - Halozyme; Rafael Pharmaceuticals
 
Harri Jarvelainen
Employment - Cend Therapeutics
Leadership - Cend Therapeutics
Stock and Other Ownership Interests - Cend Therapeutics
Patents, Royalties, Other Intellectual Property - Cend Therapeutics
 
Raed Moh'd Taiseer Al-Rajabi
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Seagen
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lexicon (Inst); Lilly (Inst); Merck (Inst); Sillajen (Inst)
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Milind A. Phadnis
No Relationships to Disclose
 
Anusha Chidharla
No Relationships to Disclose
 
Timothy Schmitt
No Relationships to Disclose
 
Sean Kumer
No Relationships to Disclose
 
Mazin Mazin Al-Kasspooles
No Relationships to Disclose
 
John Ashcraft
No Relationships to Disclose
 
Benjamin Martin
No Relationships to Disclose
 
Samuel Luka
No Relationships to Disclose
 
Mojtaba Olyaee
No Relationships to Disclose
 
Amit Rastogi
No Relationships to Disclose
 
Scott James Weir
Research Funding - CicloMed (Inst)
Patents, Royalties, Other Intellectual Property - Co-Inventor on issued Ciclopirox Prodrug composition-of-matter and methods-of-use patents
(OPTIONAL) Uncompensated Relationships - CicloMed
 
Subhrajit Saha
No Relationships to Disclose
 
Prasad Dandawate
No Relationships to Disclose
 
Rashna Madan
No Relationships to Disclose
 
Weijing Sun
Research Funding - Merck (Inst)
 
Joaquina Celebre Baranda
Stock and Other Ownership Interests - Aprea Therapeutics; Forty Seven; Hylapharm; Merus NV; Moderna Therapeutics; MorphoSys; Zymeworks
Consulting or Advisory Role - Sanofi (Inst)
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Nektar (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)